<DOC>
	<DOCNO>NCT00556634</DOCNO>
	<brief_summary>Background : Neuropsychiatric side effect ( NPSEs ) occur significant proportion subject initiation efavirenz ( EFV ) may limit use certain patient . Objectives : To evaluate incidence severity NPSEs antiviral efficacy EFV give step dosage 2 week versus usual dosage . Methods : Randomized , double blind , multicentric clinical trial progressive dosage ( arm A : 200 mg qd 6 day , 400 mg qd 7 day 600 mg qd day 14 forward ) compare conventional administration ( arm B : 600 mg qd first day ) . All patient receive additional treatment 2 NRTIs . The incidence intensity NPSEs sleep disorder assess use Likert-type scale specifically design . Efficacy assess percent virological failure .</brief_summary>
	<brief_title>Incidence Severity Neuropsychiatric Adverse Events Efavirenz Given Stepped Dosage vs. Usual Dosage</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Age old 18 year HIV1 infection Women childbearing age : negative pregnancy test Ability understand sign write consent form Pregnancy.. Illegal drug methadone use . Major psychiatric disease antecedent start new psychotropic agent last 4 week Concomitant treatment rifamycins , protease inhibitor drug interfere pharmacokinetic efavirenz . Hepatic insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>efavirenz</keyword>
	<keyword>central nervous system</keyword>
	<keyword>adverse effect</keyword>
</DOC>